Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting · NCT05855200 · Interventional (participants receive a specific treatment) · Lead sponsor: GlaxoSmithKline

View the official record on ClinicalTrials.gov →

Interventions studied

What this trial is about

The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon cancer.

Who can take part

Age range

18 Years and older

Sex

All (male and female)

Healthy volunteers

No - a diagnosis or condition is required

Phase

Phase 3

Study type

Interventional (participants receive a specific treatment)

Inclusion criteria

Has untreated pathologically confirmed colon adenocarcinoma
Has resectable colon adenocarcinoma defined as clinically T4N0 or Stage III
Has radiologically evaluable disease
Has a tumor demonstrating the presence of either dMMR status or MSI-H

Exclusion criteria

Has distant metastatic disease.
Has received prior medical therapy (chemotherapy, immunotherapy, biologic, or targeted therapy), radiation therapy or surgery for management of the current diagnosis of colon cancer
Has a tumor that, in the investigator's judgment is causing symptomatic bowel obstruction or otherwise requires urgent/emergent surgery at the time of screening. Participants with a history of colonic obstruction are eligible after obstruction is relieved by a diverting stoma (defunctioning ileostomy or colostomy). Patients with a history of colonic obstruction in the context of current colon cancer diagnosis and treated with colonic stents are not eligible.
Has undergone any major surgical procedure, open biopsy, or experienced significant traumatic injury within 28 days prior to randomization
Has any history of interstitial lung disease or pneumonitis and/or history of radiation induced enteritis.
Has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice
Has a history of allogenic stem cell transplantation or organ transplantation
Is receiving any other anticancer or experimental therapy. No other experimental therapies (including but not limited to chemotherapy, radiation, hormonal treatment, antibody therapy, immunotherapy, gene therapy, vaccine therapy, or other experimental drugs) of any kind are permitted while the participant is receiving study intervention
Is pregnant, breastfeeding, or expecting to conceive children within the projected duration of the study
Has a history of severe allergic and/or anaphylactic reactions to chimeric, human or humanized antibodies, fusion proteins, or known allergies to dostarlimab, or its excipients, or any components of FOLFOX or CAPEOX

Where it is running

60 locations listed across 25 US states.

GSK Investigational Site - Tucson, Arizona, United States
GSK Investigational Site - Los Angeles, California, United States
GSK Investigational Site - New Haven, Connecticut, United States
GSK Investigational Site - Washington D.C., District of Columbia, United States
GSK Investigational Site - Deerfield Beach, Florida, United States
GSK Investigational Site - Fort Lauderdale, Florida, United States
GSK Investigational Site - Marietta, Georgia, United States
GSK Investigational Site - Chicago, Illinois, United States
GSK Investigational Site - Chicago, Illinois, United States
GSK Investigational Site - Chicago, Illinois, United States
GSK Investigational Site - Naperville, Illinois, United States
GSK Investigational Site - Naperville, Illinois, United States
GSK Investigational Site - Westwood, Kansas, United States
GSK Investigational Site - Lexington, Kentucky, United States
GSK Investigational Site - Louisville, Kentucky, United States
GSK Investigational Site - Baton Rouge, Louisiana, United States
GSK Investigational Site - Bethesda, Maryland, United States
GSK Investigational Site - Ann Arbor, Michigan, United States
GSK Investigational Site - Detroit, Michigan, United States
GSK Investigational Site - Minneapolis, Minnesota, United States
GSK Investigational Site - Joplin, Missouri, United States
GSK Investigational Site - St Louis, Missouri, United States
GSK Investigational Site - St Louis, Missouri, United States
GSK Investigational Site - Grand Island, Nebraska, United States
GSK Investigational Site - Omaha, Nebraska, United States
GSK Investigational Site - Omaha, Nebraska, United States
GSK Investigational Site - Lebanon, New Hampshire, United States
GSK Investigational Site - New York, New York, United States
GSK Investigational Site - New York, New York, United States
GSK Investigational Site - New York, New York, United States
GSK Investigational Site - New York, New York, United States
GSK Investigational Site - The Bronx, New York, United States
GSK Investigational Site - Durham, North Carolina, United States
GSK Investigational Site - Akron, Ohio, United States
GSK Investigational Site - Cincinnati, Ohio, United States
GSK Investigational Site - Cleveland, Ohio, United States
GSK Investigational Site - Cleveland, Ohio, United States
GSK Investigational Site - Cleveland, Ohio, United States
GSK Investigational Site - Oklahoma City, Oklahoma, United States
GSK Investigational Site - Oklahoma City, Oklahoma, United States
GSK Investigational Site - Pittsburgh, Pennsylvania, United States
GSK Investigational Site - Sioux Falls, South Dakota, United States
GSK Investigational Site - Sioux Falls, South Dakota, United States
GSK Investigational Site - Sioux Falls, South Dakota, United States
GSK Investigational Site - Sioux Falls, South Dakota, United States
GSK Investigational Site - Dallas, Texas, United States
GSK Investigational Site - Dallas, Texas, United States
GSK Investigational Site - Richmond, Virginia, United States
GSK Investigational Site - Appleton, Wisconsin, United States
GSK Investigational Site - Aalst, Belgium
GSK Investigational Site - Aichi, Japan
GSK Investigational Site - Almada, Portugal
GSK Investigational Site - Ankara, Turkey (Türkiye)
GSK Investigational Site - Ankara, Turkey (Türkiye)
GSK Investigational Site - Ankara, Turkey (Türkiye)
GSK Investigational Site - Athens, Greece
GSK Investigational Site - Badajoz, Spain
GSK Investigational Site - BaracaldoVizcaya, Spain
GSK Investigational Site - Barcelona, Spain
GSK Investigational Site - Barcelona, Spain

Showing 60 of 266 listed sites. See the official record for the complete list.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →